Le Lézard
Classified in: Health, Science and technology
Subjects: Photo/Multimedia, Personnel

Sema4 Appoints Biotech Leader Joel Sendek as Chief Financial Officer


Sema4, a patient-centered health intelligence company, today announced the appointment of Joel Sendek as Chief Financial Officer. Mr. Sendek has more than 25 years of financial leadership experience in the pharmaceutical and biotechnology sector, including overseeing the successful initial public offerings at his last two companies.

"As Sema4's growth continues to accelerate, building relationships with patients and providers to provide more actionable clinical guidance, Joel's experience with fundraising and running the finances of publicly traded companies will be invaluable," said Eric Schadt, Ph.D., Founder and Chief Executive Officer of Sema4. "I am delighted to welcome him to our rapidly growing team and look forward to the significant contributions he will make for us and for the patients, physicians, and healthcare systems we're helping every day."

Mr. Sendek commented: "Sema4 has already made tremendous strides in health intelligence and genomic testing, and I believe the company is now poised for even more transformative growth. I am excited to join this vibrant company as it brings better care to the fields of oncology, women's health, and beyond."

Previously, Mr. Sendek served as Chief Financial Officer at Spero Therapeutics for more than two years and held the same position at Forward Pharma the three years before that. He spent more than 15 years as a senior equity research analyst covering the biotech field and leading healthcare equity research at Stifel Financial Corp. and Lazard. Prior to his career in equity research, Mr. Sendek worked as a Senior Director of Corporate Development at Progenics Pharmaceuticals and as an investment banking analyst at Goldman Sachs. He earned his B.A. in biochemistry at Rice University.

About Sema4

Sema4 is a patient-centered health intelligence company founded on the idea that more information, deeper analysis, and increased engagement will improve the diagnosis, treatment, and prevention of disease. Sema4 is dedicated to transforming healthcare by building dynamic models of human health and defining optimal, individualized health trajectories, starting in the areas of reproductive health and oncology. Centrellistm, our innovative health intelligence platform, is enabling us to generate a more complete understanding of disease and wellness and to provide science-driven solutions to the most pressing medical needs. Sema4 believes that patients should be treated as partners, and that data should be shared for the benefit of all.

For more information, please visit sema4.com and connect with Sema4 on Twitter, LinkedIn, Facebook and YouTube.


These press releases may also interest you

at 02:00
OKX, a leading crypto exchange by trading volume and a leading Web3 technology company, has issued updates for March 29, 2024. OKX...

at 00:30
Frost & Sullivan recently researched the data center colocation services industry and, based on its findings, recognizes STT GDC India with the 2023 Indian Company of the Year Award. STT GDC India is a pioneer data center solutions provider that...

at 00:25
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial...

at 00:24
In the news release, Roborock Reports 2023 Full Year Financial Results, issued 28-Mar-2024 by Roborock over PR Newswire, we are advised by the company that in the first bullet point of "Growth across Product Categories", the USD amount should read...

28 mar 2024
The opening ceremony of the Boao Forum for Asia (BFA) Annual Conference 2024 was held in Boao, south China's Hainan Province on Thursday, with China's top legislator Zhao Leji stressing China's economic potential, appealing to international investors...

28 mar 2024
OKX Ventures, the investment arm of leading Web3 technology company OKX, has issued updates for March 29, 2024. OKX Ventures...



News published on and distributed by: